Integrative therapy using coenzyme Q10 and minocycline in 1-methyl-4-phenylpyridinium-induced hemiparkinson rats
10.3969/j.issn.1000-4718.2014.09.014
- VernacularTitle:辅酶Q10与美满霉素联合干预1-甲基-4-苯基吡啶诱导的偏侧帕金森病大鼠模型研究
- Author:
Junpeng GAO
;
Ziyi ZHOU
;
Jun XIANG
;
Yiping CHEN
;
Dingfang CAI
- Publication Type:Journal Article
- Keywords:
Parkinson disease;
Mitochondrial complex I;
Coenzyme Q10;
Microglia;
Minocycline;
Dopami-nergic neuron
- From:
Chinese Journal of Pathophysiology
2014;(9):1622-1632
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To investigate the integrative treatment of both coenzyme Q 10 ( CoQ10 ) and minocycline in the rats intranigrally intoxicated with 1-methyl-4-phenylpyridinium ( MPP+) .METHODS:The rat model of Parkinson disease ( PD) was established by intranigral microinjection of MPP +.The degree of microglial activation was measured by immuno-fluorescent density of OX-42 ( a microglia marker ) in the substantia nigra ( SN) .The number of viable dopaminergic neurons was determined by counting the tyrosine hydroxylase ( TH) positive neurons in the SN .The behavioral performances were re-vealed with the number of apomorphine-induced rotations , score of forelimb akinesia and vibrissae-elicited forelimb placing a-symmetry.RESULTS:Pretreatment with CoQ10 or intracerebroventricular (icv) posttreatment with minocycline alone pro-vided partial attenuation against MPP +-induced locomotor defects .Integrative therapy provided enhanced beneficial effects , and resulted in a significant attenuation of locomotor disability than any single therapy (all P<0.01).The results of immu-nohistological analysis showed that the TH positive neurons were maximally protected by integrative therapy compared with minocycline group and CoQ 10 group (P<0.01) .CONCLUSION:The integrative therapy of CoQ 10 combined with minocy-cline may offer additional therapeutic benefit to MPP +-induced hemiparkinson rat model .Such neuroprotective strategy of tar-geting different aspect of the neurodegenerative phenotypes may highlight a new therapeutic strategy for future management of PD.
